Shandong Xinhua Pharmaceutical Gains Key Drug Approval

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the supplementary application of the lactulose oral solution, facilitating a change in the marketing authorization holder. This approval follows an agreement with Beijing Minkangbaicao Medicine Technology Co., Ltd. for a technology transfer, including rights to marketing and sales. This strategic move is set to enhance Xinhua Pharmaceutical’s market presence in the pharmaceutical industry.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.